DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,999 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $3,926,393 | -6.7% | 15,715 | -6.7% | 0.40% | +35.1% |
Q1 2024 | $4,206,284 | +288.7% | 16,844 | +292.4% | 0.30% | +214.9% |
Q1 2023 | $1,082,008 | -45.8% | 4,293 | -43.0% | 0.09% | -41.2% |
Q4 2022 | $1,997,551 | -2.2% | 7,526 | -4.8% | 0.16% | -7.5% |
Q3 2022 | $2,042,000 | -37.7% | 7,904 | -38.8% | 0.17% | -37.5% |
Q2 2022 | $3,277,000 | -9.3% | 12,925 | +4.9% | 0.28% | -2.1% |
Q1 2022 | $3,613,000 | +291.4% | 12,316 | +339.2% | 0.28% | +379.7% |
Q4 2021 | $923,000 | -32.4% | 2,804 | -44.9% | 0.06% | -14.5% |
Q2 2021 | $1,366,000 | +70.1% | 5,090 | +42.6% | 0.07% | +30.2% |
Q1 2021 | $803,000 | +34.5% | 3,569 | +28.8% | 0.05% | -15.9% |
Q3 2020 | $597,000 | -93.2% | 2,771 | -94.4% | 0.06% | -95.3% |
Q2 2020 | $8,734,000 | -27.1% | 49,391 | -42.9% | 1.35% | -15.8% |
Q1 2020 | $11,978,000 | -15.5% | 86,540 | -6.3% | 1.60% | +20.5% |
Q4 2019 | $14,180,000 | +13.5% | 92,392 | +6.8% | 1.33% | -1.2% |
Q3 2019 | $12,494,000 | +15.7% | 86,506 | +14.5% | 1.35% | +22.9% |
Q2 2019 | $10,798,000 | +32.9% | 75,554 | +22.7% | 1.10% | +33.1% |
Q1 2019 | $8,126,000 | +121.7% | 61,554 | +73.1% | 0.82% | +98.1% |
Q4 2018 | $3,666,000 | -63.1% | 35,554 | -61.2% | 0.42% | -57.8% |
Q3 2018 | $9,948,000 | +10.1% | 91,554 | 0.0% | 0.99% | +3.6% |
Q2 2018 | $9,035,000 | -29.9% | 91,554 | -30.4% | 0.95% | -28.8% |
Q1 2018 | $12,880,000 | +78.0% | 131,554 | +68.8% | 1.34% | +90.2% |
Q4 2017 | $7,236,000 | +1.7% | 77,957 | -6.0% | 0.70% | +1.7% |
Q3 2017 | $7,116,000 | -7.3% | 82,957 | -8.8% | 0.69% | -21.6% |
Q2 2017 | $7,676,000 | -57.9% | 90,957 | -57.3% | 0.88% | -56.3% |
Q1 2017 | $18,214,000 | +11.4% | 212,957 | +1.4% | 2.02% | -51.1% |
Q4 2016 | $16,346,000 | -9.3% | 210,000 | -8.7% | 4.13% | -4.1% |
Q3 2016 | $18,030,000 | -41.1% | 230,000 | -24.1% | 4.30% | +3.5% |
Q2 2016 | $30,599,000 | +6.5% | 302,957 | 0.0% | 4.16% | +21.7% |
Q1 2016 | $28,739,000 | -5.9% | 302,957 | -7.9% | 3.42% | -7.4% |
Q4 2015 | $30,557,000 | -1.2% | 328,957 | -9.4% | 3.69% | +30.4% |
Q3 2015 | $30,929,000 | -42.6% | 362,957 | -42.3% | 2.83% | -30.0% |
Q2 2015 | $53,851,000 | +120.1% | 629,175 | +118.3% | 4.04% | +48.2% |
Q1 2015 | $24,471,000 | +24.3% | 288,175 | +25.5% | 2.72% | +28.7% |
Q4 2014 | $19,683,000 | -16.8% | 229,646 | -26.1% | 2.12% | +248.4% |
Q3 2014 | $23,649,000 | +60.2% | 310,942 | +65.9% | 0.61% | -62.8% |
Q2 2014 | $14,758,000 | – | 187,483 | – | 1.63% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |